FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology. There are presented stem cells produced by culturing human monocytes in the presence of (i) M-CSF in the concentration of 5 to 100 ng/ml and (ii) at least one representative specified in a group consisting of ganglioside in the concentration of 1 to 100 mcg/ml and a water-soluble herbal extract produced by Folch extraction, in the concentration from 0.1 to 100 mcg/ml, thereby differentiating monocytes, wherein the expression of CSCR4 gene of the above stem cells is more than three or four times as much as the expression by the stem cells produced by culturing human monocytes in the presence of M-CSF and IL-3, and the expression of CSCR4 gene of the above stem cells is more than two or three times as much as the expression by mesenchymal stem cells taken from bone marrow, for treating the diseases associated with cell damages, tissue or organ damages.
EFFECT: there are presented stem cells produced by culturing human monocytes.
15 cl, 7 dwg, 3 tbl, 2 ex
